来自Lawsone的Mannich基抑制PKM2并诱导新生细胞死亡
Lucas Rubini-Dias1, Tácio V A Fernandes2, Michele P de Souza3
1Programa de Pós-Graduação em Ciências Morfológicas, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Fundão, Rio de Janeiro 21941-590, RJ, Brazil.
Biomedicines
|January 8, 2025
概括
一种新的曼尼希基,MB-6a,在癌细胞中选择性地向酸盐激酶M2 (PKM2),抑制葡萄糖代谢和ATP产生. 癌细胞代谢的这种干扰提供了一个有前途的治疗策略.
科学领域:
- 生物化学 生物化学
- 癌症新陈代谢 癌症新陈代谢
- 药物发现 药物发现 药物发现
背景情况:
- 酸盐激酶M2 (PKM2) 是癌细胞代谢的关键调节剂,也是癌症治疗的目标.
- 破坏PKM2的代谢适应性是一种抑制瘤细胞生长的策略.
- 法律一种衍生的曼尼希基MB-6a正在研究其抑制PKM2.2的潜力.
研究的目的:
- 评估MB-6a对各种癌症细胞系的抗增殖作用.
- 通过MB-6a.来研究体外和体内抑制酸盐激酶M2 (PKM2) 的抑制.
- 阐明MB-6a影响癌细胞代谢和ATP生产的机制.
主要方法:
- 通过MTT测定在SCC-9,Hep-G2,HT-29,B16-F10和HGF细胞系中评估的抗增殖活性.
- 使用LDH合试验和ATP生产测量评估的PKM2抑制.
- 在分析中包括了MB-6a与PKM2.2的分子对接和分子动力学模拟.
主要成果:
- MB-6a对测试的癌细胞系表现出选择性细胞毒性,在SCC-9 (4.63) 中具有高选择性指数.
- 该化合物有效地抑制了PKM2的糖解活性,减少了酶分析和治疗细胞中的ATP产生.
- 对接和MD模拟表明MB-6a与PKM2的良好结合,通过关键分子相互作用稳定.
结论:
- MB-6a通过破坏癌细胞葡萄糖代谢和降低ATP水平来表现出抗增殖活性.
- 该化合物诱导癌细胞的能量崩,突出其作为PKM2向剂的潜力.
- 作为主要化合物,MB-6a显示出进一步研究和在癌症治疗中潜在的临床应用的前景.
相关概念视频
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
01:23Negative Regulator Molecules
35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K